Last reviewed · How we verify
Suganon (EVOGLIPTIN)
At a glance
| Generic name | EVOGLIPTIN |
|---|---|
| Sponsor | Dong-A ST |
| Target | Dipeptidyl peptidase 4 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) (PHASE2,PHASE3)
- Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database
- Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes (PHASE4)
- Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE3)
- Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE3)
- The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients (PHASE1)
- Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases (PHASE4)
- Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |